| 1 |
Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Al B. Benson et al. · Journal of the National Comprehensive Cancer Network
|
May 2021 |
1,068 |
| 2 |
Cholangiocarcinoma
Paul J. Brindley, Melinda Bachini, Sumera Irie Ilyas et al. · Nature Reviews Disease Primers
ReviewOpen access |
9 Sep 2021 |
889 |
| 3 |
Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline
Rachna T. Shroff, Erin B. Kennedy, Melinda Bachini et al. · Journal of Clinical Oncology
|
11 Mar 2019 |
459 |
| 4 |
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study
Do‐Youn Oh et al. · The Lancet. Gastroenterology & hepatology
Open access |
29 May 2024 |
297 |
| 5 |
NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023
Al B. Benson et al. · Journal of the National Comprehensive Cancer Network
Open access |
Jul 2023 |
213 |
| 6 |
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial
Howard A. Burris, Takuji Okusaka, Arndt Vogel et al. · The Lancet Oncology
|
29 Apr 2024 |
148 |
| 7 |
Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study
Do‐Youn Oh, Aiwu Ruth He, Shukui Qin et al. · Journal of Hepatology
Open access |
15 May 2025 |
87 |
| 8 |
American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care
Nathan A. Pennell et al. · Journal of Clinical Oncology
Open access |
8 Dec 2020 |
87 |
| 9 |
Cholangiocarcinoma 2026: status quo, unmet needs and priorities
Jesús M. Bañales et al. · Nature Reviews Gastroenterology & Hepatology
ReviewOpen access147 authors |
10 Dec 2025 |
74 |
| 10 |
Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Al B. Benson et al. · Journal of the National Comprehensive Cancer Network
|
Sep 2025 |
52 |
| 11 |
Luteolin Arrests Cell Cycling, Induces Apoptosis and Inhibits the JAK/STAT3 Pathway in Human Cholangiocarcinoma Cells
Ploypailin Aneknan, Veerapol Kukongviriyapan, Auemduan Prawan et al. · Asian Pacific Journal of Cancer Prevention
Open access |
30 Jun 2014 |
51 |
| 12 |
‘IHPBA-APHPBA clinical practice guidelines’: international Delphi consensus recommendations for gallbladder cancer
Jagannath Palepu et al. · HPB
Open access |
26 Jul 2024 |
32 |
| 13 |
Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma
Kristen Renee Spencer et al. · JNCI Journal of the National Cancer Institute
Open access |
11 Apr 2023 |
32 |
| 14 |
Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies
Alessandro Parisi et al. · European Journal of Cancer
Open access |
6 Feb 2024 |
24 |
| 15 |
Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial
Daniel H. Palmer et al. · Journal of Clinical Oncology
Open access |
5 Dec 2024 |
22 |
| 16 |
Recommendations on Perihilar Cholangiocarcinoma. The Milan Jury-Based Consensus
Matthias Pfister, Francesca Ratti, Gregory J. Gores et al. · Annals of Surgery
Open access |
6 Jun 2025 |
21 |
| 17 |
Cholangiocarcinoma Targeted Therapies
Haley Ellis, Chiara Braconi, Juan W. Valle et al. · American Journal Of Pathology
Open access |
19 Dec 2024 |
21 |
| 18 |
Gold Nanoparticles Enhance the Anticancer Activity of Gallic Acid against Cholangiocarcinoma Cell Lines
Narintorn Rattanata, Sakda Daduang, Molin Wongwattanakul et al. · Asian Pacific Journal of Cancer Prevention
Open access |
4 Nov 2015 |
21 |
| 19 |
Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference
Ghassan K. Abou‐Alfa et al. · Journal of Gastrointestinal Oncology
Open access |
Dec 2016 |
20 |
| 20 |
Intrahepatic cholangiocarcinoma: Insights on molecular testing, targeted therapies, and future directions from a multidisciplinary panel
Rushabh Gujarathi, Supriya Peshin, Xuchen Zhang et al. · Hepatology Communications
Open access |
9 Jun 2025 |
19 |
| 21 |
The Cholangiocarcinoma in the Young (CITY) Study: Tumor Biology, Treatment Patterns, and Survival Outcomes in Adolescent Young Adults With Cholangiocarcinoma
Leontios Pappas et al. · JCO Precision Oncology
Open access |
Aug 2023 |
17 |
| 22 |
Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomised, controlled, open-label, phase III umbrella trial (SAFIR-ABC10—Precision Medicine)
David Malka, Ivan Borbath, Andre Lopes et al. · ESMO Open
Open access |
9 Apr 2025 |
15 |
| 23 |
Understanding Patient Experience in Biliary Tract Cancer: A Qualitative Patient Interview Study
Nikunj Ramanikbhai Patel, Xandra Lie, Chad J. Gwaltney et al. · Oncology and Therapy
Open access |
10 Jul 2021 |
15 |
| 24 |
The 2024 ILTS-ILCA consensus recommendations for liver transplantation for HCC and intrahepatic cholangiocarcinoma
Sudha Kodali et al. · Liver Transplantation
Open access |
27 Feb 2025 |
14 |
| 25 |
Priorities to Promote Participant Engagement in the Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network
Anne L. R. Schuster et al. · Cancer Epidemiology Biomarkers & Prevention
Open access |
15 Feb 2023 |
14 |
| 26 |
Treatment Patterns and Survival in Locally Advanced or Metastatic Biliary Tract Cancer Using SEER Medicare Data
Mark D. Danese, Kabir Mody, Ramya Thota et al. · Gastro Hep Advances
Open access |
2023 |
12 |
| 27 |
Patient reported outcomes: Financial toxicity is a barrier to clinical trials and personalized therapy in cholangiocarcinoma
Jessica Millian Keilson, Stacie C. Lindsey, Melinda Bachini et al. · Journal of Surgical Oncology
Open access |
15 Jul 2022 |
11 |
| 28 |
Diagnostic journey and life impact of cholangiocarcinoma: results from surveys of patient and caregiver experiences
Kristen B. Bibeau, T. Jackson, Melinda Bachini et al. · Future Oncology
Open access |
5 Dec 2023 |
9 |
| 29 |
Novel Mutations in Cholangiocarcinoma with Low Frequencies Revealed by Whole Mitochondrial Genome Sequencing
Kanha Muisuk, Atit Silsirivanit, Kanokwan Imtawil et al. · Asian Pacific Journal of Cancer Prevention
Open access |
18 Mar 2015 |
9 |
| 30 |
Genetic and epigenetic alterations of RIZ1 and the correlation to clinicopathological parameters in liver fluke-related cholangiocarcinoma
Prasong Khaenam, Patcharee Jearanaikoon, Chawalit Pairojkul et al. · Experimental and Therapeutic Medicine
Open access |
2010 |
9 |
| 31 |
279MO Three-year survival, safety and extended long-term survivor (eLTS) analysis from the phase III TOPAZ-1 study of durvalumab (D) plus chemotherapy in biliary tract cancer (BTC)
D-Y. Oh, Aiwu Ruth He, Shukui Qin et al. · Annals of Oncology
Open access |
Jun 2024 |
8 |
| 32 |
Perspectives of the medical oncologist regarding adjuvant chemotherapy for pancreatic cancer: An international expert survey and case vignette study
N C Biesma et al. · European Journal of Surgical Oncology
Open access |
12 Dec 2024 |
7 |
| 33 |
Amplifying the Patient's Voice in Oncology Early-Phase Clinical Trials: Solutions to Burdens and Barriers
Kristen Renee Spencer, Henry Butenschoen, Emily Alger et al. · American Society of Clinical Oncology Educational Book
Open access |
Jun 2024 |
7 |
| 34 |
Cholangiocarcinoma classification: current approach, relevance and challenges
Benjamin Goeppert, Yoh Zen, Juan W. Valle et al. · Journal of Clinical Pathology
|
14 Dec 2024 |
5 |
| 35 |
Treatment options for biliary tract cancer: unmet needs, new targets and opportunities from both physicians' and patients' perspectives
Rachna T. Shroff, Melinda Bachini · Future Oncology
Open access |
30 May 2024 |
5 |
| 36 |
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer
Florian Castet et al. · Journal of Hepatology
Open access117 authors |
3 Jun 2025 |
4 |
| 37 |
Screening and surveillance practices for Multiple Endocrine Neoplasia type 1‐related Neuroendocrine Tumours in European Neuroendocrine Tumor Society Centers of Excellence ( ENETS CoE )—An ENETS MEN1 task force questionnaire study
Carolina R C Pieterman et al. · Journal of Neuroendocrinology
Open access |
26 Nov 2024 |
4 |
| 38 |
A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer
James J. Harding et al. · Future Oncology
Open access |
8 Aug 2024 |
4 |
| 39 |
Durvalumab Plus Chemotherapy for Advanced Biliary Tract Cancer
Do-Youn Oh, Aiwu Ruth He, Shukui Qin et al. · JAMA Oncology
Open access |
9 Jul 2026 |
3 |
| 40 |
139P KEYNOTE-966: 3-year follow-up for pembrolizumab (pembro) + gemcitabine and cisplatin (gem/cis) vs placebo (pbo) + gem/cis for patients (pts) with advanced biliary tract cancer (BTC)
M. Ueno, Richard S. Finn, Changhoon Yoo et al. · Annals of Oncology
Open access |
Dec 2024 |
3 |
| 41 |
55P Subsequent anticancer therapy (SAT) analysis from 3-year follow-up of the phase III TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in biliary tract cancer (BTC)
A. Vogel, D-Y. Oh, Aiwu Ruth He et al. · Annals of Oncology
Open access |
Sep 2024 |
3 |
| 42 |
Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analyses
Younghun Han et al. · Hepatology
|
2 Feb 2026 |
2 |
| 43 |
82P Genomic alterations in biliary tract cancer and association with patient outcomes: Translational data from patients treated on the randomised phase III multicentre BILCAP clinical trial
Valerie Elizabeth Crolley, Rachel Victoria Guest, Andrew David Beggs et al. · Annals of Oncology
Open access |
Sep 2025 |
2 |
| 44 |
320P First-line therapy (1L) of cisplatin/gemcitabine (CisGem) with pembrolizumab (pembro) in patients with advanced biliary tract cancer (aBTC): Open-label, single-arm phase II EORTC-1607-GITCG/ABC-09 intergroup study with translational research (TR)
M. Moehler, Annett Maderer, Daniel‐Christoph Wagner et al. · Annals of Oncology
Open access |
Jul 2025 |
2 |
| 45 |
391P Phase II results of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in patients with pancreatic and biliary tract cancer
J.A. Bridgewater, L. Chantrill, R. Gillmore et al. · Annals of Oncology
Open access |
Jun 2024 |
2 |
| 46 |
Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer
Lipika Goyal et al. · Future Oncology
Open access |
17 Jun 2024 |
2 |
| 47 |
Guidelines for Management of Urgent Symptoms in Patients with Cholangiocarcinoma and Biliary Stents or Catheters Using the Modified RAND/UCLA Delphi Process
Renuka V. Iyer, Susan G. Acquisto, John A. Bridgewater et al. · Cancers
Open access |
21 Aug 2020 |
2 |
| 48 |
Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study
Stephen Lam Chan, Thomas Yau, R. K. Kelley et al. · Cancer Research Communications
Open access |
27 Feb 2026 |
1 |
| 49 |
Broadening the gates: Analysis of potentially modifiable study entry criteria in pancreatic and biliary tract cancer trials
Fen Saj, Felicity K. Namayanja, Lianchun Xiao et al. · Cancer
Open access |
19 Dec 2025 |
1 |
| 50 |
Transplant oncology: keeping the patient's perspective in mind
Melinda Bachini, R. Mark Ghobrial · Current Opinion in Organ Transplantation
|
23 Dec 2024 |
1 |